- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07801872
Assessment of Six-minute Walking Distance 6MWD Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
31. August 2026 aktualisiert von: Silvia Ulrich Somaini
Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes
To study the effect of descent from high altitude (Quito Ecuador: 2850m) to sea level on six-minute walking distance and scores in healthy individuals, who live permanently >2600m.
Studienübersicht
Status
Noch keine Rekrutierung
Intervention / Behandlung
Detaillierte Beschreibung
The aim of this research is to investigate the six-minute walking distance and scores before and after descent (high altitude near their living altitude vs. sea level) in healthy individuals, who permanently live at high altitude over 2600m.
Studientyp
Interventionell
Einschreibung (Geschätzt)
14
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Silvia Ulrich, Prof. Dr. med.
- Telefonnummer: +41442552220
- E-Mail: silvia.ulrich@usz.ch
Studieren Sie die Kontaktsicherung
- Name: Michael Furian, Prof. Dr. sc. ETH
- Telefonnummer: +41442552220
Studienorte
-
-
-
Zurich, Schweiz, 8091
- University Hospital of Zurich
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria:
- Adults aged 18-80 years and of all genders
- Permanent residence > 2600 m
- healthy: no self-perceived cardiopulmonary disease limiting daily activities
- written informed consent to participate in the study
Exclusion Criteria:
- Age <18 years or >80 years
- Participants who cannot follow the study investigations
- Participants permanently living < 2600m
- Participants who traveled and stayed overnight at altitudes <2000 m in the past 4 weeks.
- any self-perceived cardiopulmonary disease limiting daily activities
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Six-minute walking distance 6MWD at sea level
Assessment of the six-minute walking distance and scores near their resident altitude at 2850m followed by a descent from 2850m to sea level by bus with a stay for 7 days and again assessment of the same outcomes
|
Descent from 2850m to sea level with stay for 7 days
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Six-minute walking distance after 7 days at sea level
Zeitfenster: From high altitude (2850m) to day 5-7 at sea level
|
Difference/change in six-minute walking distance in meter (6MWD) between 2850m and Day 5-7 at sea level in healthy individuals
|
From high altitude (2850m) to day 5-7 at sea level
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
SpO2 (%) at rest and end-exercise after 7 days at sea level
Zeitfenster: From high altitude (2850m) to day 5-7 at sea level
|
Difference/change in SpO2 (peripheral oxygen saturation) at rest and end-exercise between 2850m and Day 5-7 at sea level in healthy individuals
|
From high altitude (2850m) to day 5-7 at sea level
|
|
Heart rate (beats per minute) at rest and end-exercise after 7 days at sea level
Zeitfenster: From high altitude (2850m) to day 5-7 at sea level
|
Difference/change in heart rate at rest and end-exercise between 2850m and Day 5-7 at sea level in healthy individuals
|
From high altitude (2850m) to day 5-7 at sea level
|
|
Blood pressure (mmHg) at rest and end-exercise after 7 days at sea level
Zeitfenster: From high altitude (2850m) to day 5-7 at sea level
|
Difference/change in blood pressure at rest and end-exercise between 2850m and Day 5-7 at sea level in healthy individuals
|
From high altitude (2850m) to day 5-7 at sea level
|
|
Dyspnea and leg discomfort sensation after 7 days at sea level
Zeitfenster: From high altitude (2850m) to day 5-7 at sea level
|
Difference/change in dyspnea and leg discomfort sensation (assessed with BORG-CR10-Scale, Category Rating 0-10 with 10 being the most dyspnea/leg discomfort) at rest and end-exercise between 2850m and 5-7 days at sea level in healthy individuals
|
From high altitude (2850m) to day 5-7 at sea level
|
|
NYHA functional class (1-4) after 7 days at sea level
Zeitfenster: From high altitude (2850m) to day 5-7 at sea level
|
Difference/change in NYHA functional class (New York Heart Association Class I-IV, IV being the worst) at rest and end-exercise between 2850m and 5-7 days at sea level in healthy individuals
|
From high altitude (2850m) to day 5-7 at sea level
|
|
Quality of life after 7 days at sea level
Zeitfenster: From high altitude (2850m) to day 5-7 at sea level
|
Difference/change in quality of life score (EmPHasis-10: Score with 10 questions and 0-50 points, higher scores indicating poorer quality of life) between 2850m and 5-7 days at sea level in healthy individuals
|
From high altitude (2850m) to day 5-7 at sea level
|
|
General well-being after 7 days at sea level
Zeitfenster: From high altitude (2850m) to Day 5-7 at sea level
|
Difference/change in general well-being (Visual Analog Scale 10cm: the higher, the worse) between 2850m and day 5-7 at sea level in healthy individuals
|
From high altitude (2850m) to Day 5-7 at sea level
|
|
Acclimatization-effect of six-minute walking distance (m) at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in six-minute walking distance (6MWD) within a stay at sea level of 7 days (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
|
Acclimatization-Effect of SpO2 (%) at rest and end-exercise at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in SpO2 (peripheral oxygen saturation) at rest and end-exercise within a stay at sea level of 7 days (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
|
Acclimatization-Effect of heart rate (beats per minute) at rest and end-exercise at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in heart rate at rest and end-exercise within a stay at sea level of 7 days (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
|
Acclimatization-Effect of blood pressure (mmHg) at rest and end-exercise at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in blood pressure at rest and end-exercise within a stay at sea level of 7 days (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
|
Acclimatization-Effect of dyspnea and leg discomfort at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in dyspnea and leg discomfort (assessed with BORG-CR10-Scale, Category Rating 0-10 with 10 being the most dyspnea/leg discomfort) at rest and end-exercise within a stay at sea level of 7 days (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
|
Acclimatization-Effect of NYHA functional class (1-4) at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in NYHA functional class (New York Heart Association Class I-IV, IV being the worst) at rest and end-exercise within a stay of 7 days at sea level (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
|
Acclimatization-Effect of Quality of Life at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in quality of life (EmPHasis-10: Score with 10 questions and 0-50 points, higher scores indicating poorer quality of life) within a stay of 7 days at sea level (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
|
Acclimatization-Effect of general well-being at sea level
Zeitfenster: From Day 2 to Day 5-7 at sea level
|
Difference/change in general well-being (Visual Analog Scale 10cm: the higher, the worse) within a stay of 7 days at sea level (after descent from 2850m) in healthy individuals
|
From Day 2 to Day 5-7 at sea level
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Silvia Ulrich, University Hospital Zurich, Departement of Pulmonology
- Hauptermittler: Rodrigo Hoyos, Hospital Carlos Andrade Marin of Quito, Ecuador
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
25. September 2026
Primärer Abschluss (Geschätzt)
4. Oktober 2026
Studienabschluss (Geschätzt)
31. Dezember 2026
Studienanmeldedaten
Zuerst eingereicht
17. August 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
31. August 2026
Zuerst gepostet (Tatsächlich)
3. September 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
3. September 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
31. August 2026
Zuletzt verifiziert
1. August 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Ec_HAvsLA_6MWD_H
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Beschreibung des IPD-Plans
Data will be provided upon request and based on a clear intention reviewed by an ethical review board.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .